VERAXA Biotech Reports Positive Preclinical Data for BiTAC-ADC Platform, Advancing Next-Generation Cancer Therapies

VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).

The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results underscore the potential of the BiTAC approach to enhance the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.

VERAXA’s proprietary BiTAC platform is designed to overcome limitations of conventional ADCs, which can cause off-target toxicity. By integrating a tumor-specific activation mechanism, BiTAC-ADCs aim to concentrate the cytotoxic payload at the tumor site, reducing harm to normal tissues. The company’s pipeline includes multiple antibody-based formats, including antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and other formats, all leveraging this precision engineering.

The company recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. This listing provides VERAXA with access to capital markets to advance its pipeline and pursue strategic collaborations. The company is presenting both its BiTAC-ADC and BiTAC-TCE platforms at the BIO International Convention, signaling its intent to partner with larger pharmaceutical firms to accelerate development.

For investors, the latest news and updates relating to VRXA are available in the company’s newsroom at https://nnw.fm/VRXA. The successful demonstration of in vitro proof-of-concept marks an important milestone for VERAXA, though the platform has not yet entered clinical trials. The company maintains a diversified oncology pipeline, positioning itself as a potential partner for next-generation cancer therapies.